- Published: October 2010
- Region: China, Global
China Healthcare Company Analysis - Nanjing Pharmaceutical
- Published: December 2012
- Region: Global, China
- 30 pages
There are many big local companies that are playing key roles in the Chinese healthcare industry, covering biotech, medical technology and pharmaceutical markets. With more local resources and better understanding of the Chinese market, these local companies had achieved enough shares and are the key competitors of most multinational companies.
Nanjing Pharmaceutical is one of the largest drug distribution and retail companies in China. With its more than 80 subsidiary companies and strong networks around China, it had achieved revenues of RMB 17.2 billion in 2011. This report will provide you with more insightful information of Nanjing Pharmaceutical, covering its history, business, revenues and costs, people, shareholders and subsidiaries, recent activities and future development.
Purely focusing on the Chinese healthcare industry, ChinaBionews is able to track and dig more detailed information with Shanghai based Chinese native analysts. Before delivering the report, ChinaBionews will check if there is any new info available, such as quarterly revenues and recent activities, to make sure that the report is mostly updated.
Reasons of Buying
More original information based on the Chinese language
Detailed analysis of the company
Strong after sale support to clients who have access to Shanghai-based experienced analysts for further questions
Who should Buy
Decision makers who are looking for M&A opportunities in China
Decision makers who are responsible for market intelligence in China
Decision makers who are responsible for business development in China
Consultants SHOW LESS READ MORE >
1. Nanjing Pharmaceutical Overview
2.1 Balance Sheet
2.1.2 Liabilities & Equity
2.2.1 Annual Revenues
2.2.2 Quarterly Revenues
2.3.1 Sales & Marketing Costs
2.3.2 R&D Expenditure
2.3.3 Other Costs
3.1 Board of Director
3.2 Management Team
4.1 Risk Analysis
4.2 Recent Activities
4.3 Future Development
Nanjing Pharmaceutical Co., Ltd.